ARAI

Arrive AI is a pre-commercial idea, not a business. FY2025 revenue was $113K while net loss widened to -$12.8M (from -$4.54M the prior year, a -182.7% swing), producing a net margin of -11,325% and ROE of -518%. The MD&A is written almost entirely in the future tense — the company 'expects to have three primary revenue streams,' 'intends to,' and 'plans to' monetize AP4/AP5 units and an ADM 'marketplace' still 'in development.' Its own validation amounts to pilots with 'a regional hospital and a specialty pharmaceutical delivery company.' That is a venture-stage story trading on a public ticker, and the market cap of $18.9M capitalizes $113K of sales at 166.5x — a valuation with no fundamental anchor.

The balance sheet and cash flows compound the risk. Operating cash flow was -$8.25M against just $2.48M of stockholders' equity and liabilities of 3.42x equity; current liabilities ($6.73M) nearly triple current assets ($2.31M), a negative working-capital position. The accumulated deficit is -$28.7M. Note the reported FY2026 cash tag of '$8.20B' is implausible for an $18.9M-cap company and appears to be a mislabeled/scaling artifact in the XBRL — I do not rely on it, and its unreliability is itself a reason to treat the disclosures cautiously.